^
Association details:
Evidence:
Evidence Level:
Sensitive: C1 - Off-label
  (Approved for Melanoma)
New
Excerpt:
Vemurafenib is indicated in monotherapy for the treatment of adult patients with BRAF-V600-mutation-positive unresectable or metastatic melanoma.
Evidence Level:
Sensitive: C2 – Inclusion Criteria
New
Go to data
Title:

A Study of Vemurafenib in Participants With BRAF V600 Mutation-Positive Cancers

Excerpt:
...Confirmed diagnosis of multiple myeloma with a BRAF V600 mutation...
Trial ID:
Evidence Level:
Sensitive: C3 – Early Trials
New
Title:

BRAF Inhibition in BRAFV600-Mutant Gliomas: Results From the VE-BASKET Study

Excerpt:
Patients with BRAFV600-mutant glioma received vemurafenib 960 mg twice per day continuously...Twenty-four patients (median age, 32 years; 18 female and six male patients) with glioma, including...PXA (n = 7), anaplastic ganglioglioma (n = 3), pilocytic astrocytoma (n = 2),...Responses among patients with other tumor types included PR in one patient with PA who was treated for 15.3 months...One CR was observed in a patient with PXA, and five patients achieved PR...
DOI:
10.1200/JCO.2018.78.9990
Trial ID: